3 Cardiovascular and CNS Leader, Chronic Therapy Specialist and Largest Domestic Pharma Seller Stocks With a Strong Future Roadmap: Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma

Branded prescription drug maker stocks let investors follow companies that serve a growing part of the Indian economy. Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma cover a cardiovascular and central nervous system leader, a chronic therapy specialist and one of the largest domestic pharma sellers.

This list covers three branded prescription drug maker stocks with complete current figures: Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Branded Prescription Drug Maker Stocks?

Branded prescription drug maker stocks are listed drug makers that sell prescription and consumer health brands to doctors and patients across India. Their earnings depend on brand strength, field force reach, new launches and the share of chronic therapies.

Branded Prescription Drug Maker Stocks at a Glance

On valuation, Eris Lifesciences trades at a P/E below the industry P/E, while Torrent Pharmaceuticals and Mankind Pharma trade above it, which reflects the growth the market already expects. Readers comparing branded prescription drug maker stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in branded prescription drug maker stocks can use the coming numbers to test whether growth is holding.

Why Do Branded Prescription Drug Maker Stocks Have a Strong Roadmap in India?

Branded prescription drug maker stocks have a strong roadmap in India because rising healthcare access, longer life spans and a growing chronic disease burden keep lifting demand for trusted branded medicines.

• Chronic therapies. Long-term treatments for heart, diabetes and stomach care give repeat demand.
• Field force reach. Large doctor networks help new launches scale.
• Consumer health. Trusted over-the-counter brands widen the customer base.

Why Torrent Pharmaceuticals Features Among These Branded Prescription Drug Maker Stocks

Among the branded prescription drug maker stocks on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.

Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%.

In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.

Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.

Why Eris Lifesciences Features Among These Branded Prescription Drug Maker Stocks

Among the chronic therapy drug maker shares on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.

In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%.

Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.

Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.

Why Mankind Pharma Features Among These Branded Prescription Drug Maker Stocks

Among the three companies on this list, Mankind Pharma is one of India's largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.

The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0.

Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore.

Roadmap: The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.

What to watch: Watch the market share in chronic therapies and the integration of acquired brands.

Torrent Pharmaceuticals vs Eris Lifesciences vs Mankind Pharma on Key Financials

The table below sets the three branded prescription drug maker stocks side by side on revenue, profit and margin, using reported figures.

Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Mankind Pharma has the largest FY26 revenue at Rs 14,636 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with branded prescription drug maker stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Branded Prescription Drug Maker Stocks

Every theme carries risks that deserve a check before any decision. For these branded prescription drug maker stocks, the main points are: Long-term chronic therapy drug maker shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Price controls. Government pricing rules can affect some medicines.
• Competition. Many companies compete for doctor attention.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter branded prescription drug maker stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Branded Prescription Drug Maker Stocks

Branded prescription drug maker stocks reward investors who follow demand trends, order books and margins together. Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma each have a clear plan to grow their brands. Based on the 23 October 2026 close, Torrent Pharmaceuticals trades at Rs 4,524.4, Eris Lifesciences at Rs 1,095.5 and Mankind Pharma at Rs 2,212.6. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these branded prescription drug maker stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track branded prescription drug maker stocks, set price alerts and get research-backed stock ideas.

What are branded prescription drug maker stocks?

Ans. Branded prescription drug maker stocks are listed drug makers that sell prescription and consumer health brands to doctors and patients across India. Their earnings depend on brand strength, field force reach, new launches and the share of chronic therapies. This list looks at three of them, Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.

Which branded prescription drug maker stocks are covered in this list?

Ans. This list covers Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma. Based on the 23 October 2026 close, Torrent Pharmaceuticals traded at Rs 4,524.4, Eris Lifesciences at Rs 1,095.5 and Mankind Pharma at Rs 2,212.6. Their return on equity ranges from 11.7% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 22.9%.

Why do branded prescription drug maker stocks have a strong future roadmap in India?

Ans. Branded prescription drug maker stocks have a strong roadmap in India because rising healthcare access, longer life spans and a growing chronic disease burden keep lifting demand for trusted branded medicines. The main drivers are as follows. Chronic therapies. Long-term treatments for heart, diabetes and stomach care give repeat demand. Field force reach. Large doctor networks help new launches scale. Consumer health. Trusted over-the-counter brands widen the customer base. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Torrent Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

How has Eris Lifesciences performed financially?

Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

How has Mankind Pharma performed financially?

Ans. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.

What risks should investors check before buying branded prescription drug maker stocks?

Ans. Investors should check a few risks before buying branded prescription drug maker stocks. Price controls. Government pricing rules can affect some medicines. Competition. Many companies compete for doctor attention. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of branded prescription drug maker stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.